nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

25.03.2017 | Research Article

An updated review of cardiac devices in heart failure

verfasst von: C. Murphy, H. Zafar, F. Sharif

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Heart failure has the highest rates of adult hospitalisations, the highest mortality rates and significant costs associated with its care. The cost of heart failure is expected continue to grow on a global scale, with $108 billion spent on heart failure in 2012. Mortality rates are high, with incident cases of heart failure resulting in 30% 1-year mortality, and in hospital mortality of acute heart failure, 28%.

Methods and Results

This article reviews the devices currently in use for the treatment of heart failure, as well as those that are under investigation. A review of the mechanism of action of devices, the literature supporting their application as therapy, and the cost effectiveness associated with their use are discussed. Conventional techniques discussed herein include the guideline-supported therapies of mechanical circulatory support (MCS) and cardiac resynchronisation therapy (CRT). Novel devices that are discussed include invasive physiological monitoring, neuromodulation, percutaneous ventricular assist devices (VADs) and cardiac contractility modulation (CCM). There has been advancement in mechanical circulatory support devices for the treatment of both acute and chronic heart failure. In addition to MCS, only CRT has resulted in reduced mortality.

Conclusion

Due to the clinical and economic arguments, treatment of heart failure is said to be the biggest unmet need in cardiology today. The data reviewed herein support this statement.

Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137–1146CrossRefPubMedPubMedCentral

Yturralde RF, Gaasch WH (2005) Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis 47:314–319CrossRefPubMed

Reynolds HR, Hochman JS (2008) Cardiogenic shock: current concepts and improving outcomes. Circulation 117:686–697CrossRefPubMed

Hunt SA, Abraham WT, Chin MH et al (2009) Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed. J Am Coll Cardiol 53:e1–e90CrossRefPubMed

Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur J Heart Fail 10:933–989CrossRefPubMed

Yancy CW, Lopatin M, Stevenson LW et al (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A Report From the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76–84CrossRefPubMed

Bhatia RS, Tu JV, Lee DS et al (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260–269CrossRefPubMed

Bleumink GS, Knetsch AM, Sturkenboom MCJM et al (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614–1619CrossRefPubMed

MacIntyre K, Capewell S, Stewart S et al (2000) Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation 102:1126–1131CrossRefPubMed

10.

McMurray JJV, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur Heart J 33:1787–1847CrossRefPubMed

11.

Cook C, Cole G, Asaria P et al (2014) The annual global economic burden of heart failure. Int J Cardiol 171:368–376CrossRefPubMed

12.

Lloyd-Jones D, Adams R, Carnethon M et al (2009) Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119:e21–e181CrossRefPubMed

13.

Slaughter MS, Pagani FD, McGee EC et al (2013) HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 32:675–683CrossRefPubMed

14.

World’s First Endovascular Neuromodulation Device Implanted in Man for the Treatment of Congestive Heart Failure|Journal of Invasive Cardiology. http://www.invasivecardiology.com/news/worlds-first-endovascular-neuromodulation-device-implanted-man-treatment-congestive-heart. Accessed 18 Feb 2016

15.

Rose EA, Gelijns AC, Moskowitz AJ et al (2001) Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345:1435–1443CrossRefPubMed

16.

Kirklin JK, Naftel DC, Pagani FD et al (2012) Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? J Thorac Cardiovasc Surg 144:584–603CrossRefPubMedPubMedCentral

17.

Slaughter MS, Rogers JG, Milano CA et al (2009) Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361:2241–2251CrossRefPubMed

18.

Kirklin JK, Naftel DC, Kormos RL et al (2011) Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 30:115–123CrossRefPubMed

19.

Aaronson KD, Slaughter MS, Miller LW et al (2012) Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 125:3191–3200CrossRefPubMed

20.

Stretch R, Sauer CM, Yuh DD et al (2014) National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol 64:1407–1415CrossRefPubMed

21.

Kirklin JK, Naftel DC, Pagani FD et al (2014) Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant 33:555–564CrossRefPubMed

22.

Rogers JG, Bostic RR, Tong KB et al (2012) Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail 5:10–16CrossRefPubMed

23.

Birks EJ (2010) The comparative use of ventricular assist devices: differences between Europe and the United States. Tex Heart Inst J 37:565–567PubMedPubMedCentral

24.

Shuhaiber JH, Jenkins D, Berman M et al (2008) The Papworth experience with the Levitronix CentriMag ventricular assist device. J Heart Lung Transplant 27:158–164CrossRefPubMed

25.

Gilotra NA, Stevens GR (2014) Temporary mechanical circulatory support: a review of the options, indications, and outcomes. Clin Med Insights Cardiol 8:75–85PubMed

26.

John R, Long JW, Massey HT et al (2011) Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg 141:932–939CrossRefPubMed

27.

Cheng JM, Den Uil CA, Hoeks SE et al (2009) Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 30:2102–2108CrossRefPubMed

28.

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) AF, Steg PG, James SK et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33: 2569–2619

29.

Kirkpatrick JN, Wieselthaler G, Strueber M et al (2015) Ventricular assist devices for treatment of acute heart failure and chronic heart failure. Heart 101:1091–1096CrossRefPubMed

30.

Burkhoff D, Cohen H, Brunckhorst C et al (2006) A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 152:469(e1–e8)CrossRef

31.

Thiele H, Lauer B, Hambrecht R et al (2001) Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 104:2917–2922CrossRefPubMed

32.

Kapur NK, Paruchuri V, Jagannathan A, et al. 307 Mechanical circulatory support for right ventricular failure: The TandemHeart in RIght VEntricular Support (THRIVE) Registry. J Hear Lung Transplant 31. doi:10.1016/j.healun.2012.01.315. (Epub ahead of print 2012)

33.

O’Neill WW, Kleiman NS, Moses J et al (2012) A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation 126:1717–1727CrossRefPubMed

34.

Thiele H, Zeymer U, Neumann F-J et al (2013) Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet (London, England) 382:1638–1645CrossRef

35.

Smith EJ, Reitan O, Keeble T et al (2009) A first-in-man study of the reitan catheter pump for circulatory support in patients undergoing high-risk percutaneous coronary intervention. Catheter Cardiovasc Interv 73:859–865CrossRefPubMed

36.

McAlister FA, Ezekowitz J, Hooton N et al (2007) Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 297:2502–2514CrossRefPubMed

37.

Brignole M, Auricchio A, Baron-Esquivias G et al (2013) 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 34:2281–2329CrossRefPubMed

38.

Tracy CM, Epstein AE, Darbar D et al (2012) 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm S. Circulation 126:1784–1800CrossRefPubMed

39.

Brignole M, Auricchio A, Baron-Esquivias G et al (2013) 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Europace 15:1070–1118CrossRefPubMed

40.

Bax JJ, Abraham T, Barold SS et al (2005) Cardiac resynchronization therapy: part 2—issues during and after device implantation and unresolved questions. J Am Coll Cardiol 46:2168–2182CrossRefPubMed

41.

Kashani A, Barold SS (2005) Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 46:2183–2192CrossRefPubMed

42.

Adabag S, Roukoz H, Anand IS et al (2011) Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis. J Am Coll Cardiol 58:935–941CrossRefPubMed

43.

Feldman AM, de Lissovoy G, Bristow MR et al (2005) Cost effectiveness of cardiac resynchronization therapy in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial. J Am Coll Cardiol 46:2311–2321CrossRefPubMed

44.

Fox M, Mealing S, Anderson R et al (2007) The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess 11: iii–iv, ix-248

45.

Yao G, Freemantle N, Calvert MJ et al (2007) The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 28:42–51CrossRefPubMed

46.

Daubert J-C, Saxon L, Adamson PB et al (2012) 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 14:1236–1286CrossRefPubMed

47.

Costanzo MR, Guglin ME, Saltzberg MT et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49:675–683CrossRefPubMed

48.

Kwong JSW, Yu C-M (2014) Ultrafiltration for acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 172:395–402CrossRefPubMed

49.

Del Trigo M, Bergeron S, Bernier M et al (2016) Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet 387:1290–1297CrossRefPubMed

50.

Hasenfuß G, Hayward C, Burkhoff D et al (2016) A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet 387:1298–1304CrossRefPubMed

51.

Bourge RC, Abraham WT, Adamson PB et al (2008) Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 51:1073–1079CrossRefPubMed

52.

Kuck K-H, Bordachar P, Borggrefe M et al (2014) New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. Europace 16:109–128CrossRefPubMed

53.

Magalski A, Adamson P, Gadler F et al (2002) Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. J Card Fail 8:63–70CrossRefPubMed

54.

Yu C-M, Wang L, Chau E et al (2005) Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 112:841–848CrossRefPubMed

55.

Ritzema J, Melton IC, Richards AM et al (2007) Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation 116:2952–2959CrossRefPubMed

56.

Troughton RW, Ritzema J, Eigler NL et al (2011) Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance. J Cardiovasc Transl Res 4:3–13CrossRefPubMed

57.

Ritzema J, Troughton R, Melton I et al (2010) Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 121:1086–1095CrossRefPubMed

58.

Maurer MS, Adamson PB, Costanzo MR et al (2015) Rationale and design of the left atrial pressure monitoring to optimize heart failure therapy study (LAPTOP-HF). J Card Fail 21:479–488CrossRefPubMed

59.

Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658–666CrossRefPubMed

60.

Olshansky B, Sabbah HN, Hauptman PJ et al (2008) Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 118:863–871CrossRefPubMed

61.

Domanski M (2003) A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 9:354–363CrossRefPubMed

62.

Kuck K-H, Cappato R, Siebels J et al (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 102:748–754CrossRefPubMed

63.

De Ferrari GM, Crijns HJGM, Borggrefe M et al (2011) Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 32:847–855CrossRefPubMed

64.

Schwartz PJ, De Ferrari GM, Sanzo A et al (2008) Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 10:884–891CrossRefPubMed

65.

Gold MR, Van Veldhuisen DJ, Hauptman PJ et al (2016) Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. doi:10.1016/j.jacc.2016.03.525 (Epub ahead of print 29 March 2016)

66.

Zipes DP, Neuzil P, Theres H et al (2016) Determining the feasibility of spinal cord neuromodulation for the treatment of chronic systolic heart failure: the DEFEAT-HF Study. JACC Heart Fail 4:129–136CrossRefPubMed

67.

Tse H-F, Turner S, Sanders P et al (2015) Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment (SCS HEART study): first-in-man experience. Heart Rhythm 12:588–595CrossRefPubMed

68.

Lovett EG, Schafer J, Kaufman CL (2009) Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies. In: Conf Proceedings Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf 2009, pp 4626–4630

69.

Georgakopoulos D, Little WC, Abraham WT et al (2011) Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail 17:167–178CrossRefPubMed

70.

Brandt MC, Madershahian N, Velden R et al (2011) Baroreflex activation as a novel therapeutic strategy for diastolic heart failure. Clin Res Cardiol 100:249–251CrossRefPubMed

71.

Abraham WT, Lindenfeld J, Reddy VY et al (2015) A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS Duration: study rationale and design. J Card Fail 21:16–23CrossRefPubMed

72.

Giallauria F, Vigorito C, Piepoli MF et al (2014) Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: an individual patient’s data meta-analysis of randomized controlled trials. Int J Cardiol 175:352–357CrossRefPubMed

73.

Radlberger P, Adlbrecht C, Mittermayr T (2011) Cardiac contractility modulation in patients with heart failure refractory to drug treatment. Exp Clin Cardiol 16:43–46PubMedPubMedCentral

74.

Chamogeorgakis T, Rafael A, Shafii AE et al (2013) Which is better. ASAIO J 59:607–611CrossRefPubMed

75.

Tsao N-W, Shih C-M, Yeh J-S et al (2012) 2012 Extracorporeal membrane oxygenation–assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock. J Crit Care 27:530(e1–e11)CrossRef

76.

Sheu J-J, Tsai T-H, Lee F-Y et al (2010) Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 38:1810–1817CrossRefPubMed

77.

Amat-Santos IJ, Bergeron S, Bernier M et al (2015) Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure: first-in-man experience with the V-Wave device. Eurointervention 10:1127–1131CrossRefPubMedPubMedCentral

78.

Anker SD, Coats AJS, Cristian G et al (2015) A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J 36:2297–2309CrossRefPubMedPubMedCentral

79.

Sutton MG, Sharpe N (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101:2981–2988CrossRefPubMed

80.

Cilingiroglu M, Rollefson WA, Mego D (2013) Percutaneous implantation of a parachute device for treatment of ischemic heart failure. Cardiovasc Revasc Med 14:236–240CrossRefPubMed

81.

Costa MA, Pencina M, Nikolic S et al (2013) The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. Am Heart J 165:531–536CrossRefPubMed

Titel: An updated review of cardiac devices in heart failure
verfasst von: C. Murphy
H. Zafar
F. Sharif
Publikationsdatum: 25.03.2017
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 4/2017
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-017-1597-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods and Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Failure to control hypercholesterolaemia in the Irish adult population: cross-sectional analysis of the baseline wave of The Irish Longitudinal Study on Ageing (TILDA)

Nitrate-rich beetroot juice selectively lowers ambulatory pressures and LDL cholesterol in uncontrolled but not controlled hypertension: a pilot study

Development and evaluation of a centralised computerised registry for ureteric stents: completing the audit cycle

Impact of Xpert MRSA/SA blood culture PCR assay on management of positive blood cultures in obstetric patients: a retrospective audit

Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge